This ACE Clinical Guidance (ACG) provides evidence-based recommendations on selecting an appropriate anticoagulant and treatment duration for different patient groups with venous thromboembolism (VTE), such as patients from the general population (including those with severe renal impairment or liver disease) and those with active cancer. Guidance on when to extend therapy is also provided.
A supplementary guide on switching between anticoagulants is included.
First published in 2018, the ACG on VTE treatment has been updated to incorporate the latest evidence where relevant.
Download the PDF below to access the full ACG.
Registered doctors, pharmacists and nurses may claim 1 Continuing Medical Education (CME)/Continuing Professional Education (CPE) point under category 3A/ category V-B for reading each ACG.
| ACG recommendations |
|---|
| 1. | Start anticoagulation as soon as possible for patients with confirmed proximal DVT or PE, unless contraindicated. |
| 2. | For patients from the general population, use a DOAC for at least 3 months as the preferred anticoagulant for VTE treatment; consider warfarin as an alternative if DOACs are not suitable. |
| 3. | For patients with cancer needing VTE treatment, use apixaban, edoxaban, rivaroxaban, or LMWH for the initial and treatment phases for at least 6 months; LMWH is preferred if the patient has gastrointestinal cancer. |
VTE - Treating with the appropriate anticoagulant and duration (May 2024)
VTE - Treating with the appropriate anticoagulant and duration – references (May 2024)
Feedback
Click here to give us feedback on this ACG.
Related ACGs